MaxCyte (MXCT)

• Market cap: $120M
• 1 day: 1.82%
• 5 days: -4.27%
• 1 month: 36.22%
• 3 months: 34.13%
• 6 months: -26.32%
• Year to date: -27.74%
• 1 year: -50.66%
• 5 years: -93.41%
• 10 years: -93.41%
• Sector: Healthcare
• Industry: Medical Devices

About: MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Employees: 91